Assessing IMCD (ENXTAM:IMCD) Valuation After CFO Successor Named and Supervisory Board Reappointments
IMCD (ENXTAM:IMCD) just laid out its next chapter in finance leadership, nominating long time insider Floris Lagerwerf as CFO from 2027 while keeping its Supervisory Board largely intact to support continuity.
See our latest analysis for IMCD.
Even with this steady handover at the top, IMCD’s share price return has been weak, with a year to date slide that mirrors a three and five year total shareholder return firmly in negative territory. This suggests momentum has clearly faded despite ongoing growth in revenues and earnings.
If this leadership shift has you reassessing your watchlist, it could be a good moment to explore fast growing stocks with high insider ownership for other fast growing, high conviction ideas.
With the shares down sharply over one, three, and five years despite continued revenue and profit growth and a hefty discount to analyst targets, is IMCD now an undervalued compounder in transition, or is the market correctly pricing in slower future growth?
Most Popular Narrative Narrative: 39.5% Undervalued
Compared with IMCD’s last close at €76.98, the most followed narrative points to a fair value closer to €127, implying substantial upside potential based on long term cash flows.
IMCD's strategic expansion into high growth and resilient end markets (pharma, food and nutrition, personal care) through both organic efforts and targeted M and A increases exposure to industries with strong, recurring demand fundamentals, which can support sustainable revenue and margin expansion as macro uncertainty fades.
Want to see what kind of revenue runway and margin reset could justify such a big gap to today’s price? The narrative leans on steady compounding, disciplined acquisitions, and a richer profit mix to support that higher fair value. Curious how those moving parts add up to this case for upside potential? Dive in to unpack the full playbook behind this valuation call.
Result: Fair Value of €127.18 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, several risks could derail this upside case, including prolonged weak industrial demand and FX headwinds that keep reported growth and margins under pressure.
Find out about the key risks to this IMCD narrative.
Build Your Own IMCD Narrative
If you see the story differently or want to dig into the numbers yourself, you can craft a personalized thesis in just minutes: Do it your way.
A great starting point for your IMCD research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
Ready for your next investing move?
Shift from watching to acting by using the Simply Wall St Screener to uncover fresh, data driven stock ideas that could reshape your portfolio’s next chapter.
- Capture potential mispricings by scanning these 907 undervalued stocks based on cash flows that look cheap against their cash flows and future prospects.
- Ride powerful innovation trends by zeroing in on these 26 AI penny stocks poised to benefit from accelerating adoption of artificial intelligence.
- Strengthen your income stream by targeting these 13 dividend stocks with yields > 3% that can support regular cash returns alongside long term growth.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com